International Oncology Network - Cancer & Hematology News
Share 'Regorafenib Shows Statistically Significant Improvement in OS in Patients with mCRC Refractory to Standard Approved Therapies'
The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA. Regorafenib (BAY 73-4506) is an an investigational oral multi-kinas…
You can share this blog post in two ways…
© 2013 Created by Peter Hofland, PhD.
